MARKET

GRAL

GRAL

Grail Inc
NASDAQ
68.69
-0.10
-0.15%
Opening 13:27 07/08 EDT
OPEN
66.21
PREV CLOSE
68.79
HIGH
69.48
LOW
66.00
VOLUME
335.36K
TURNOVER
--
52 WEEK HIGH
118.84
52 WEEK LOW
29.95
MARKET CAP
2.95B
P/E (TTM)
-6.6219
1D
5D
1M
3M
1Y
5Y
1D
GRAIL, Inc. (GRAL) Securities Class Action Filed Following NHS-Galleri Trial Failure and $2.2 Billion Market Cap Loss -- HBSS
PR Newswire · 16h ago
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead the Grail Class Action Lawsuit
PR Newswire · 1d ago
GRAL Investment Deadline: GRAIL, Inc. Securities Fraud Class Action Focuses on Trial Results; Investors Notified of August 4 Court Deadline
PR Newswire · 1d ago
GRAIL (GRAL) Could Be 5% Overvalued Following Trial Miss And Class Actions
Simply Wall St · 1d ago
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
PR Newswire · 2d ago
Weekly Report: what happened at GRAL last week (0629-0703)?
Weekly Report · 2d ago
GRAIL: FDA Approval Could Unlock Vast Potential
Seeking Alpha · 3d ago
Is NHS-Galleri Trial Miss and New Lawsuits Altering The Investment Case For GRAIL (GRAL)?
Simply Wall St · 4d ago
More
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Webull offers Grail Inc stock information, including NASDAQ: GRAL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRAL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRAL stock methods without spending real money on the virtual paper trading platform.